DISCOVERIES (ISSN 2359-7232), 2018, October-December issue

CITATION: 

Submitted: December 4th, 2018; Revised: December 26th, 2018; Accepted: December 27th, 2018; Published: December 31st, 2018;

 GO BACK to 2018, October-December issue

 GO BACK to DISCOVERIES

HER2 Oncogene Amplification and Immunohistochemical Profiling in Gastric Adenocarcinoma

Nisha Raj (1), Divya Verma (1), Ashok Kumar (2), Praveer Rai (3), Ram Nawal Rao (1,*)

(1) Department of Pathology, Sanjay Gandhi Post Graduate Institute of Medical Sciences, Lucknow, India 

(2) Department of Surgical Gastroenterology, Sanjay Gandhi Post Graduate Institute of Medical Sciences, Lucknow, India

(3) Department of Gastroenterology, Sanjay Gandhi Post Graduate Institute of Medical Sciences, Lucknow, India

*Corresponding author: Prof. Ram Nawal Rao, MD, Department of Pathology, Sanjay Gandhi Post Graduate Institute of Medical Sciences, Rae Bareli Road, P.O. Box-226014, Lucknow, Uttar Pradesh, India; Tel.: 0522-2495259; E-mail: rnawalrao@gmail.com

Abstract

Background & Objectives: Gastric adenocarcinoma is one of the most common malignant tumors and a major cause of cancer death worldwide, especially in developing countries. Her2/neu gene amplification and protein overexpression in breast cancer is a golden criterion for the targeted therapy with trastuzumab. However, the role of Her2 as a prognostic factor in gastric cancer is still controversial. The purpose of this study was to evaluate the frequency of Her2 oncogene overexpression and concordance between the results for Her2 protein expression and gene amplification.

Materials & Methods: A total of 65 retroprospective cases with gastric adenocarcinoma, including biopsy and resected specimens obtained between July 2015 to December 2017, were analyzed. Her2/neu expression was determined by Immuno-histochemistry (IHC). Equivocal and some selected cases were submitted for FISH to detect Her2/neu gene amplification.

Results: In the present study, out of 65 patients of gastric adenocarcinoma, there were 50 males and 15 females, with mean age of 54.52 years. The majority of tumors were located within the antropyloric region. We found 27 (41.4%) positivity, scored as IHC 3+ and IHC 2+, and 38 (58.3%) negativity, scored as IHC 1+ and IHC 0. We also evidentiated a significant difference between Her2/neu expression with age (p=0.010) and depth of invasion (p=0.020).

Her2/neu gene was amplified only in 13 cases, 4 cases were of Her2/neu (3+) positive, 11 cases (39.3%) Her2/neu (2+) with IHC staining. The concordance rate between the results of IHC and FISH in all 18 cases was 83.3%.

Conclusion: IHC detection can be carried out to guide the treatment when FISH detection cannot be performed. Overexpression of Her 2/neu in gastric adenocarcinoma could potentially be used in selecting the patients who can get benefit from the anti-Her2/neu targeted therapy.

Patients specimens for this study were acquired and used under the IEC number 2017-21-PhD-95.

Access full text of the manuscript here: Full text (pdf)

References

1. Danaei G, Vander Hoorn S, Lopez AD, Murray CJ, Ezzati M. Causes of cancer in the world: comparative risk assessment of nine behavioural and environmental risk factors. Lancet. 2005; 366:1784–1793.

2. Catalano V, Labianca R, Beretta GD, Gatta G, de Braud F, Van Cutsem E. Gastric cancer. Crit Rev Oncol Hematol. 2009; 71:127–164.

3. Yeole BB. Trends in cancer incidence in esophagus, stomach, colon, rectum and liver in males in India. Asian Pac J Cancer Prev 2008; 9:97-100.

4. Satyanarayana L, Asthana S. Life time risk for development of ten major cancers in India and its trends over the years 1982 to 2000. Indian J Med Sci 2008; 62:35-44.

5. Rastogi T, Devesa S, Mangtani P, et al. Cancer incidence rates among South Asians in four geographic regions: India, Singapore, UK and US. Int J Epidemiol 2008; 37:147-60.

6. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011; 61:69–90.

7.Theuer CP, de Virgilio C, Keese G, French S, Arnell T, Tolmos J, Klein S, Powers W, Oh T, Stabile BE. Gastric adenocarcinoma in patients 40 years of age or younger. Am J Surg. 1996; 172:473–476; discussion 473-476.

8. Nakamura T, Yao T, Niho Y, Tsuneyoshi M. A clinicopathological study in young patients with gastric carcinoma. J Surg Oncol. 1999; 71:214–219.

9.Yasui W, Sentani K, Sakamoto N, et al. Molecular pathology of gastric cancer: research and practice. Pathol Res Pract. 2011; 207:608–12.

10. Nobili S, Bruno L, Landini I, et al. Genomic and genetic alterations influence the progression of gastric cancer. World J Gastroenterol. 2011; 17:290–9.

11. Sun M, Nie FQ, Wang ZX, et al. Involvement of lncRNA dysregulation in gastric cancer. Histol Histopathol. 2015; 21:11655.

12. Gravalos C, Jimeno A. Her2 in gastric cancer: a new prognostic factor and a novel therapeutic target. Ann Oncol. 2008;19(9):1523-29.

13. Rajagopal I, Niveditha SR, Sahadev R, Nagappa PK, Rajendra SG. Her2 expression in gastric and Gastro-Esophageal Junction (GEJ) adenocarcinomas. J Clin Diagn Res. 2015;9:EC06-10.

14. He C, Bian XY, Ni XZ, Shen DP, Shen YY, Liu H, Shen ZY, Liu Q. Correlation of human epidermal growth factor receptor 2 expression with clinicopathological characteristics and prognosis in gastric cancer. World J Gastroenterol. 2013; 19:2171–2178.

15. Janjigian YY, Werner D, Pauligk C, Steinmetz K, Kelsen DP, Jäger E, Altmannsberger HM, Robinson E, Tafe LJ, Tang LH, et al. Prognosis of metastatic gastric and gastroesophageal junction cancer by Her2 status: A European and USA International collaborative analysis. Ann Oncol. 2012; 23:2656–2662.

16. Baykara M, Benekli M, Ekinci O, Irkkan SC, Karaca H, Demirci U, Akinci MB, Unal OU, Dane F, Turkoz FP, et al. Clinical Significance of Her2 Overexpression in Gastric and Gastroesophageal Junction Cancers. J Gastrointest Surg. 2015; 19:1565–1571.

17. Kurokawa Y, Matsuura N, Kimura Y, Adachi S, Fujita J, Imamura H, Kobayashi K, Yokoyama Y, Shaker MN, Takiguchi S, et al. Multicenter large-scale study of prognostic impact of Her2 expression in patients with resectable gastric cancer. Gastric Cancer. 2015; 18:691–697.

18. Allgayer H, Babic R, Gruetzner KU, Tarabichi A, Schildberg FW, Heiss MM. c-erbB-2 is of independent prognostic relevance in gastric cancer and is associated with the expression of tumor-associated protease systems. J Clin Oncol. 2000; 18:2201–2209.

19. Grabsch H, Sivakumar S, Gray S, Gabbert HE, Müller W. Her2 expression in gastric cancer: Rare, heterogeneous and of no prognostic value - conclusions from 924 cases of two independent series. Cell Oncol. 2010; 32:57–65.

20. Kim KC, Koh YW, Chang HM, Kim TH, Yook JH, Kim BS, Jang SJ, Park YS. Evaluation of Her2 protein expression in gastric carcinomas: comparative analysis of 1,414 cases of whole-tissue sections and 595 cases of tissue microarrays. Ann Surg Oncol. 2011; 18:2833–2840.

21. Park DI, Yun JW, Park JH, Oh SJ, Kim HJ, Cho YK, Sohn CI, Jeon WK, Kim BI, Yoo CH, et al. Her2/neu amplification is an independent prognostic factor in gastric cancer. Dig Dis Sci. 2006; 51:1371–1379.

22. Wang S, Zheng G, Chen L, Xiong B. Effect of Her2/neu over-expression on prognosis in gastric cancer: a meta-analysis. Asian Pac J Cancer Prev. 2011; 12:1417–1423.

23. Abrahão-Machado LF, Jácome AA, Wohnrath DR, dos Santos JS, Carneseca EC, Fregnani JH, Scapulatempo-Neto C. Her2 in gastric cancer: comparative analysis of three different antibodies using whole-tissue sections and tissue microarrays. World J Gastroenterol. 2013; 19:6438–6446.

24. Jørgensen JT, Hersom M. Her2 as a Prognostic Marker in Gastric Cancer - A Systematic Analysis of Data from the Literature. J Cancer. 2012; 3:137–144.

25. E. U. Cidon, R. G. Centeno, E. G. Lagarto, and J. I. Peral. Her2 Evaluation in a Specific Gastric Cancer Population with the Highest Rate of Mortality in Spain. Journal of Oncology.2011; 2011; Article ID 391564, 6 pages.

26. Y. Yonemura, I. Ninomiya, A. Yamaguchi et al., “Evaluation of immunoreactivity for erbB-2 protein as a marker of poor short term prognosis in gastric cancer,” Cancer Research, 1991; 51(3):1034–1038.

27.T. Ishida, M. Tsujisaki, Y. Hanzawa et al., “Significance of erbB-2 gene product as a target molecule for cancer therapy,” Scandinavian Journal of Immunology, 1994, 39(5):459–466.

28. A. Tokunaga, M. Onda, T. Okuda et al., “Clinical significance of epidermal growth factor (EGF), EGF receptor, and c-erbB-2 in human gastric cancer,” Cancer, 75(6):1418–1425.

29. Sekaran A, Kandagaddala RS, Darisetty S, Lakhtakia S, Ayyagari S, Rao GV, et al. Her2 expression in gastric cancer in Indian population--an immunohistochemistry and fluorescence in situ hybridization study. Indian J Gastroenterol. 2012; 31:106–10.

30. Patil PS, Mehta SA, Mohandas KM. Over-expression of Her2 in Indian patients with gastric cancer. Indian J Gastroenterol. 2013; 32:350.

31.Kataoka Y, Okabe H, Yoshizawa A, Minamiguchi S, Yoshimura K, Haga H, et al. Her2 expression and its clinicopathological features in resectable gastric cancer. Gastric Cancer. 2013;16: 84–93.

32. Terashima M, Kitada K, Ochiai A, Ichikawa W, Kurahashi I, Sakuramoto S, et al. Impact of expression of human epidermal growth factor receptors EGFR and ERBB2 on survival in stage II/III gastric cancer. Clin Cancer Res. 2012; 18:5992–6000.

33. M. Hofmann et al., Assessment of a Her2 scoring system for gastric cancer: results from a validation study, Histopathology 2008; 52(7):797–805.

34. Ruschoff J, Hanna W, Bilous M et al. HER2 testing in gastric cancer: a practical approach. Mod Pathol, 2012; 25: 637–50.

35. Tomonori Y Ano et. al. Comparison of HER2 gene amplification assessed by fluorescence in situ hybridization and HER2 protein expression assessed by immunohistochemistry in gastric cancer. Oncology reports15: 2006, 65-71.

36. Michael F. Press et. al. Assessing the New American Society of Clinical Oncology/College of American Pathologists Guidelines for HER2 Testing by Fluorescence in Situ Hybridization. Arch Pathol Lab Med—Vol 140, 2016:1250-1258.

37. Wu WK, Cho CH, Lee CW, Fan D, Wu K, Yu J, Sung JJ. Dysregulation of cellular signaling in gastric cancer. Cancer Lett 2010; 295: 144-153.

38. Yamashita K, Sakuramoto S, Watanabe M. Genomic and epigenetic profiles of gastric cancer: potential diagnostic and therapeutic applications. Surg Today 2011; 41: 24-38.

39. Jan Trost Jorgensen. Role of human epidermal growth factor receptor 2 in gastric cancer: Biological and pharmacological aspects. World J Gastroenterol 2014 April 28; 20(16): 4526-4535.

40. Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, ToGA Trial. Trastuzumab Investigators in combination with chemotherapy versus chemotherapy alone for treatment of Her2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open label, randomized controlled trial. Lancet. 2010;376(9742):687-97.

41. Zeeneldin AA, Ramadan H, El Gammal MM, Saber MM, Elgamal D, Sherisher MA. Gastric carcinoma at Tanta Cancer Center: a comparative retrospective clinico-pathological study of the elderly versus the non-elderly. J Egypt Natl Canc Inst. 2014; 26:127-137.

42. Ahmed Abdel Hadi et.al. Her2/neu Protein Expression and Oncogene Amplification in Gastric Carcinoma with Clinico-Pathological Correlation in Egyptian Patients. Journal of Medical Sciences. 2016 Dec 15; 4(4):535-542.

43. Rüschoff J, Dietel M, Baretton G, et al. Her2 diagnostics in gastric cancer-guideline validation and development of standardized immunohistochemical testing. Virchows Arch. 2010; 457:299–307.

44. Bartlett JM, Forsyth A. Detection of Her2 gene amplification by fluorescence in situ hybridization in breast cancer. Methods Mol Med. 2006; 120:309–22.

45. Varis A, Zaika A, Puolakkainen P, et al. Coamplified and overexpressed genes at ERBB2 locus in gastric cancer [J]. Int J Cancer, 2004,109:548- 553.

46. Kim MA, Jung EJ, Lee HS, et al. Evaluation of Her2 gene status in gastric carcinoma using immunohistochemistry, fluorescence in situ hybridization, and real-time quantitative polymerase chain reaction [J]. Hum Pathol, 2007,38:1386-1393.

47. Lakshmi V, Valluru VR, Madhavi J, Valluru N. Role of Her 2 Neu in Gastric Carcinoma-3 Year Study in a Medical College Hospital. Ind J Appl Res. 2014;4(11):47–50.

48. Nisha Raj, Divya Verma, Ashok Kumar, et. al. Prognostic significance of membrane associated human epidermal growth factor receptors 2 in gastric adenocarcinomas. WJPR. 2018; 20184-11025. 

49. Sutapa Halder, Debjani Mallick,et.al. Detection and Significance of Human Epidermal Growth Factor Receptor 2 Expression in Gastric Adenocarcinoma. Indian J Med Paediatr Oncol. 2017 Apr-Jun; 38(2): 153–157.

50. Ling Shan, Jianming Ying, Ning Lu. Her2 expression and relevant clinicopathological features in gastric and gastresophageal junction adenocarcinoma in a Chinese population. Diagnostic Pathology. 2013; 8:76, doi 10.11.86/1746-1596-8-76.

51. Tafe LJ, Janjigian YY, Zaidinski M, Hedvat CV, Hameed MR, Tang LH, et al. Human epidermal growth factor receptor 2 testing in gastresophageal cancer: correlation between immunohistochemistry and fluorescence in situ hybridization. Archives of pathology & laboratory medicine. 2011;135(11):1460-65.

52. Daniela Lazar, Sorina Taban, I Sporea. Gastric cancer: correlation between clinicopathological factors and survival of patients. Romanian Journal of Morphology and Embryology. 2009;50(2):185–93.

53. Chen XZ, Zhang WH, Yao WQ, Liu JP, Zhou ZG, Chen ZX. Immunohistochemical Her2 expression not associated with clinico pathological characteristics of stage I-III gastric cancer patients. Hepatogastroenterology. 2015;61(134):1817-21.

54. Yan YS, Ying Hu, Jian-Gao Fan, Guo-Quan Tao, Yong-Ming Lu, Xu Cai. Clinicopathological significance of Her2/neu protein expression and gene amplification in gastric carcinoma. World J Gastroenterol. 2011; 17(11): 1501–1506.

55. De Carli DM, Rocha MP, Antunes LC, Fagundes RB. Immunohistochemical expression of Her2 in adenocarcinoma of the stomach. Arq Gastroenterol. 2015; 52:152–5.

56.Yan Song, et al. Correlation of HER2/ neu gene amplification and protein expression with the prognosis of advanced gastric cancer patients. Chinese Journal of Cancer 2009, 09-23.

57. Yano T, Ochiai A, Doi T, et al. Expression of Her2/neu in gastric cancer: comparison between protein expression and gene amplification using a new commercial kit [J]. J Clin Oncol, 2004,22:14S.

58. Uprak et.al. Her2 incidence in gastric cancer, its association with prognosis and clinicopathological parameters. Ulus Cerrahi Derg 2015; 31:2017-13.

59. Chao He, Xue-Yi Bian, Xing-Zhi Ni, Dan-Ping Shen et.al. Correlation of human epidermal growth factor receptor2 expression with clinicopathological characteristics and prognosis in gastric cancer. World J Gastroenterol 2013 April 14; 19(14): 2171-2178.

60. Ming Chen et.al. Comparison of Her2 status by fluorescence in situ hybridisation and immunohistochemistry in gastric cancer. Contemp Oncol (Pozn) 2014; 18 (2): 95–99.